Brief: Medicenna Provides Clinical Update From Monotherapy Dose Escalation Portion Of Phase 1/2 ABILITY Study

Medicenna Therapeutics

30/03/2023 12:27

March 30 (Reuters) - Medicenna Therapeutics Corp
 MDNA.TO :
    * MEDICENNA PROVIDES CLINICAL UPDATE FROM MONOTHERAPY DOSE
ESCALATION PORTION OF PHASE 1/2 ABILITY STUDY
    * MEDICENNA:ADDITIONAL EVIDENCE OF DURABLE ANTI-CANCER
ACTIVITY
WITH MDNA11 MONOTHERAPY SEEN IN RADIOGRAPHIC SCANS FROM FIRST
FOUR DOSE ESCALATION COHORTS
    * MEDICENNA THERAPEUTICS - DOSING IS CURRENTLY UNDERWAY IN
SIXTH
DOSE ESCALATION COHORT OF ABILITY STUDY
    * MEDICENNA THERAPEUTICS - SEES TO REPORT INITIAL ANTI-TUMOR
ACTIVITY DATA FROM ABILITY'S FIFTH DOSE ESCALATION COHORT AT
MEDICAL MEETING IN Q2 2023
    * MEDICENNA THERAPEUTICS - EARLY ANTI-TUMOR ACTIVITY DATA
FROM
ABILITY'S COMBINATION ARM EVALUATING MDNA11 PLUS PEMBROLIZUMAB
EXPECTED IN Q4 2023

Source text for Eikon:  ID:nGNX10GvXT 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))